Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clene Inc. (CLNN) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed, late clinical-stage biopharmaceutical issuer. These documents offer detailed insight into Clene’s development of CNM-Au8, its financial position, and the financing structures that support its ALS, MS, and Parkinson’s disease programs.
Investors can review current reports on Form 8-K that Clene files to describe material events. Recent 8-K filings have covered quarterly financial results and operating highlights, equity distribution agreements for at-the-market common stock offerings, prospectus supplements for additional share issuances, amendments to senior secured convertible promissory notes, and new note purchase agreements. Other 8-Ks reference press releases and scientific presentations, such as new clinical data from the REPAIR-MS and REPAIR-PD studies and regulatory updates following FDA Type C and Type B meetings.
Alongside 8-Ks, Clene’s broader SEC reporting (including Forms 10-K and 10-Q, when accessed through EDGAR) details research and development expenses, general and administrative costs, limited product and royalty revenue, and the impact of warrant and derivative liabilities. Filings also describe the terms of convertible notes, including maturity dates, interest capitalization, conversion prices into common stock, and change-of-control provisions, which are important for understanding potential dilution and capital structure.
On Stock Titan, CLNN filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight key elements of each filing, such as new financing terms, regulatory milestones, or changes in clinical development plans, helping readers quickly interpret complex legal and financial language. Users can also focus on items related to capital raises, note amendments, and other direct financial obligations that shape Clene’s runway for advancing CNM-Au8 through clinical trials and potential regulatory review.
Clene Inc. director David J. Matlin reported buying units of Clene stock and warrants in a private transaction that closed on January 13, 2026. He purchased 33,333 shares of common stock at a unit price of $6.50, with each unit including one share plus a Series A and a Series B warrant. Following this purchase, he held 477,824 common shares directly.
Matlin also acquired Series A warrants for 40,000 shares and Series B warrants for 93,333 shares, each initially exercisable at $6.00 per share. The Series A warrant exercise price can increase to $7.00 per share based on FDA action-date announcements or if the stock’s volume-weighted average price reaches $10.00 on a specified date. The Series B warrant exercise price can increase to $12.50 or $10.00 per share depending on FDA approval of CNM-Au8 in ALS and future volume-weighted average price thresholds.
Symbiosis II, LLC, an entity associated with 10% owner Chidozie Ugwumba, reported multiple sales of Clene Inc. common stock. On January 8, 2026, it sold 3,195 shares at $6.09 per share, leaving 750,367 shares indirectly owned. On January 9, 2026, it sold 9,075 shares at $6.27 per share, leaving 741,292 shares indirectly owned. On January 12, 2026, it sold 32,705 shares at $5.50 per share, leaving 708,587 shares of Clene common stock held indirectly through Symbiosis II, LLC.
Clene Inc. reported that on January 12, 2026 it issued a press release describing additional biomarker data for its investigational therapy CNM-Au8®. The company states this new biomarker information is intended to support a potential new drug application and preparation for an upcoming in-person meeting with the U.S. Food and Drug Administration. The 8-K mainly serves to make this press release part of the official record by filing it as an exhibit.
Clene Inc. is offering 928,333 shares of common stock together with Series A and Series B warrants in units priced at $6.50, for gross proceeds of about $6.0 million and estimated net proceeds of approximately $5.7 million before any warrant exercises. Each unit includes one share, a Series A Warrant for stock at an initial $6.00 exercise price, and a Series B Warrant with step-up exercise prices tied to future FDA and share-price milestones, with the warrants expiring in three and five years, respectively, and subject to a call feature if they are in the money. After the offering, Clene expects 11,778,307 shares outstanding, assuming no warrant exercises, and plans to use the cash mainly to fund clinical and regulatory work for its lead ALS drug candidate CNM-Au8 and other R&D and corporate purposes. The company reports recurring losses, limited cash of $7.9 million as of September 30, 2025, senior secured convertible notes with a $2.0 million minimum cash covenant, and explicitly states there is substantial doubt about its ability to continue as a going concern.
Clene Inc. reported insider share sales by a 10% owner associated with Ugwumba Chidozie, disclosed in a Form 4 filing. The transactions involved indirect holdings of Clene common stock through Symbiosis II, LLC.
Symbiosis II, LLC sold 5,869 shares at $5.87 on January 5, 2026, 3,111 shares at $6.04 on January 6, 2026, and 3,938 shares at $6.29 on January 7, 2026. Following the last sale, Symbiosis II, LLC indirectly held 753,562 shares of Clene common stock.
Clene Inc. reported insider selling of common stock by a 10% owner in December 2025. The Form 4 shows a series of open-market sales coded "S" from 12/03/2025 through 12/18/2025, with individual trades ranging from 2,884 to 72,748 shares at prices between $5.70 and $7.86 per share. All transactions involved Clene common stock held indirectly through Symbiosis II, LLC.
After these sales, the reporting person beneficially owned 393,150 shares of Clene common stock, held indirectly via Symbiosis II, LLC as of 12/18/2025. No derivative securities transactions were reported, as the derivative securities table is blank.
Clene Inc. (CLNN) disclosed a director stock option grant. On 11/13/2025, the director received an option for 1,893 shares of common stock at an exercise price of $7.30 per share under the Amended 2020 Stock Plan. The option vests immediately upon grant and expires on 11/12/2035.
Following the transaction, the filing shows 1,893 derivative securities beneficially owned, held in direct ownership.
Clene Inc. (CLNN) reported a director equity award on Form 4. On November 13, 2025, the director received a stock option covering 2,438 shares of common stock at an exercise price of $7.30 per share under the Clene Inc. Amended 2020 Stock Plan. The option vests immediately upon grant and carries an expiration date of November 12, 2035.
The filing classifies the transaction as an acquisition of derivative securities and lists direct ownership following the grant.
Clene Inc. (CLNN) reported an insider equity award. A director filed a Form 4 disclosing a stock option grant for 2,887 shares of common stock at an exercise price of $7.30 per share on November 13, 2025. The options vest immediately upon grant under the Clene Inc. Amended 2020 Stock Plan and carry an expiration date of November 12, 2035. Following the transaction, the filing shows 2,887 derivative securities beneficially owned with direct ownership.
Clene Inc. (CLNN) reported a stock-based compensation award to one of its directors. On November 13, 2025, the director received a stock option covering 2,816 shares of Clene common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $7.30 per share and vests immediately, meaning the director can exercise it right away, subject to plan terms. The option is scheduled to expire on November 12, 2035 if not exercised.